Back to search

University of British Columbia

Targeted synthetic disease-modifying antirheumatic drugs among mothers with autoimmune disease : pharmacoepidemiologic studies

Abstract

dc:description

Background: Active autoimmune disease during pregnancy increases risk of adverse maternal and neonatal outcomes. Targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) have significantly expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their patterns of use effects on pregnancy. Objectives: 1) Comprehensively map the literature on the impact of tsDMARDs on pregnancy outcomes in individuals with autoimmune diseases; 2) Characterize patterns of tsDMARD utilization among mothers of childbearing age with autoimmune disease; 3a) Characterize patterns of tsDMARD utilization during the perinatal period; and 3b) Evaluate the association between perinatal tsDMARD exposure and maternal and neonatal outcomes. Methods: For objective 1, I conducted a scoping review including studies that examined tsDMARD exposure in mothers during pregnancy, fathers before conception, and/or fetuses/neonates in-utero. For objective 2, I used population-based administrative health data in British Columbia to identify mothers with autoimmune diseases, summarized demographics of mothers who filled ≥1 tsDMARD prescription, and assessed drug utilization trends between January 1st, 2002 and March 31st, 2022. For objective 3a, I assessed patterns of utilization and discontinuation within the perinatal period. For objective 3b, I evaluated associations between perinatal tsDMARD exposure and maternal and neonatal outcomes. Results: 1) Of 6,712 studies screened, 8 were included. The most frequently reported outcomes were congenital anomaly (n=4) and preterm birth (n=4). 2) Among 17,084 tsDMARD prescriptions filled by mothers diagnosed with autoimmune diseases, tofacitinib and upadacitinib were the most filled drugs. 3a) Among 19 pregnancies with ≥1 tsDMARD dispensation during the perinatal period, 7 (36.8%) pregnancies filled a tsDMARD within 1-year preconception while <5 pregnancies filled a tsDMARD during the first trimester. 3b) Of 22 maternal and neonatal outcomes evaluated (e.g., congenital anomaly, small-for-gestational-age, gestational diabetes), only preterm birth showed a significant association with tsDMARD exposure (unadjusted odds ratio 13.45, 95% confidence interval 2.12-85.21). Conclusions: This thesis provides novel insight into the patterns of use and perinatal impact of tsDMARDs in mothers with autoimmune diseases. Analytical findings contribute to future evidence syntheses to inform clinical guidelines and support family planning and treatment decision-making in patients and providers.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Pharmaceutical Sciences
Grantor dc:publisher
University of British Columbia
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Cheng, Vienna
Contributors dc:contributor
  • De Vera, Mary

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/91533

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Cheng, Vienna. Targeted synthetic disease-modifying antirheumatic drugs among mothers with autoimmune disease : pharmacoepidemiologic studies. master's thesis, University of British Columbia, 2025. http://hdl.handle.net/2429/91533